Table 1 Baseline demographics and clinical characteristics of 36 patients
From: Neutralizing monoclonal antibody in patients with coronavirus disease 2019: an observational study
Variable | Overall, N = 36 | Control group, N = 9 | AT group, N = 27 | P value* |
|---|---|---|---|---|
Age, median (IQR), years | 35 (30–48) | 26 (20–32) | 36 (32–50) | 0.01 |
Sex, male, n (%) | 24 (66.7) | 5 (55.6) | 19 (70.4) | 0.44 |
BMI, median (IQR) | 23.4 (20.5–25.5) | 19.9 (18.7–21.6) | 23.9 (22.9–25.8) | 0.01 |
Smoking, n (%) | 11 (30.6) | 3 (33.3) | 8 (29.6) | > 0.99 |
Coexisting conditions, n (%) | ||||
Hypertension, n (%) | 3 (8.3) | 0 (0.0) | 3 (11.1) | 0.56 |
Diabetes, n (%) | 2 (5.6) | 0 (0.0) | 2 (7.4) | > 0.99 |
Vaccine, n (%) | 0.77 | |||
No | 29 (80.6) | 7 (77.8) | 22 (81.5) | |
First dose | 2 (5.6) | 0 (0.0) | 2 (7.4) | |
Second dose | 5 (13.9) | 2 (22.2) | 3 (11.1) | |
Disease severity, n (%) | 0.07 | |||
Mild | 9 (25.0) | 5 (55.6) | 4 (14.8) | |
Moderate | 24 (66.7) | 4 (44.4) | 20 (74.1) | |
Severe | 3 (8.3) | 0 (0.0) | 3 (11.1) | |
Hospital stay, median (IQR), days | 23.5 (21.7–25.5) | 20 (17.0–25.0) | 24 (23.0–25.5) | 0.05 |
Symptoms | ||||
Cough, n (%) | 11 (30.6) | 1 (11.1) | 10 (37.0) | 0.22 |
Fever, n (%) | 8 (22.2) | 3 (33.3) | 5 (18.5) | 0.38 |
Fatigue, n (%) | 6 (16.7) | 2 (22.2) | 4 (14.8) | 0.63 |
Myalgia, n (%) | 6 (16.7) | 2 (22.2) | 4 (14.8) | 0.63 |
Expectoration, n (%) | 5 (13.9) | 2 (22.2) | 3 (11.1) | 0.58 |
Chest tightness, n (%) | 5 (13.9) | 0 (0.0) | 5 (18.5) | 0.30 |
Diarrhea, n (%) | 4 (11.1) | 1 (11.1) | 3 (11.1) | > 0.99 |
Headache, n (%) | 4 (11.1) | 0 (0.0) | 4 (14.8) | 0.55 |
Nasal congestion, n (%) | 3 (8.3) | 1 (11.1) | 2 (7.4) | > 0.99 |
Hyposmia, n (%) | 1 (2.8) | 0 (0.0) | 1 (3.7) | > 0.99 |